Skip to main content
. 2018 Oct 18;33(8):336–348. doi: 10.1089/cbr.2018.2494

FIG. 4.

FIG. 4.

68Ga-PSMA-11 PET/CT scans of a patient with metastatic castration-resistant prostate cancer before (A) and after (B, C) receiving several cycles of 225Ac-PSMA-617, a small-molecule construct. Complete imaging response and a remarkable reduction in prostate-specific antigen, a biomarker for prostate cancer, were achieved after the final treatment, demonstrating the extraordinary potential of 225Ac for TAT. This figure was reprinted with permission from ref. 89. Copyright © 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc. TAT, targeted α therapy.